---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099404"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:45:11.152549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD

## Summary
- Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
- Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.
- Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.
- Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.
- 20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-099404
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/0000950170-25-099404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099404
- JSON: https://secwatch.observer/filing/0000950170-25-099404.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.